The “Primary” Antiphospholipid SyndromeRonald A. Asherson, Graham R.V. Hughes, Munther A. Khamashta et al.|Medicine|1989Cited by 963
Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trialHannah Cohen, David Isenberg, Munther A. Khamashta et al.|The Lancet Haematology|2016Cited by 404
Endothelial cells as target for antiphospholipid antibodies. Human Polyclonal and Monoclonal Anti‐β<sub>2</sub>‐Glycoprotein I Antibodies React In Vitro with Endothelial Cells Through Adherent β<sub>2</sub>‐Glycoprotein I and Induce Endothelial ActivationNicoletta Del Papa, Pier Luigi Meroni, Takayoshi Koike et al.|Arthritis & Rheumatism|1997Cited by 290
The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosusMichael P. Cancro, Munther A. Khamashta|Journal of Clinical Investigation|2009Cited by 275